Avantor, Inc. filed an earnings press release on October 28, 2026, reporting third-quarter fiscal 2026 results and raising its full-year 2026 guidance for organic revenue growth, adjusted EPS, and free cash flow.

Key Highlights

  • Net sales of $1,698.3 million for the three months ended September 30, 2026, a reported increase of 4.6% and an organic increase of 5.2% versus the third quarter of 2025.
  • Net income of $203.4 million compared to a net loss of $711.8 million in the prior-year period; net income margin was 12.0%.
  • Diluted GAAP EPS of $0.30 and adjusted diluted EPS of $0.22 for the quarter.
  • Adjusted EBITDA of $256.9 million with an adjusted EBITDA margin of 15.1%.
  • Free cash flow of $156.2 million for the quarter; operating cash flow was $195.1 million.
  • Raised FY 2026 organic revenue growth guidance to a range of +0.75% to +1.25%, up from the prior range of -0.5% to +0.5%.
  • Total debt, gross, of $3,699.7 million and cash and cash equivalents of $464.3 million as of September 30, 2026.

Avantor Reports Q3 2026 Segment Performance and Updated Full-Year Outlook

According to the filing, Avantor (NYSE:AVTR) reported consolidated net sales of $1,698.3 million for the three months ended September 30, 2026, reflecting a reported increase of 4.6% versus the comparable prior-year quarter. Foreign currency translation had a negative impact of 0.6%, producing a 5.2% organic net sales increase. Operating income was $139.5 million with an operating income margin of 8.2%, while adjusted operating income was $227.6 million at an adjusted operating income margin of 13.4%.

The filing reported segment results for VWR Distribution and Services and Bioscience and Medtech Products. VWR Distribution and Services generated net sales of $1,233.8 million, a reported increase of 5.0% from $1,175.0 million in Q3 2025, and organic growth of 5.8%. Its adjusted operating income was $119.4 million, down from $132.0 million in the prior-year period, with an adjusted operating income margin of 9.7%. The company attributed the margin decline to unfavorable product mix and higher SG&A expenses, partially offset by higher sales volume. Bioscience and Medtech Products reported net sales of $464.5 million, up 3.5% reported and 3.6% organically, with adjusted operating income of $123.4 million at a margin of 26.6%.

On the balance sheet and updated guidance, the filing disclosed adjusted net leverage of 3.1x and GAAP net leverage of 9.6x as of September 30, 2026. Avantor raised its fiscal 2026 organic revenue growth guidance to +0.75% to +1.25% from a prior range of -0.5% to +0.5%, adjusted EPS guidance to $0.81-$0.83 from $0.80-$0.83, and free cash flow guidance to $525 million-$550 million from $500 million-$550 million. The adjusted EBITDA margin guidance range of 14.8% to 15.3% was unchanged. The company also disclosed a fully diluted share count assumption of 679 million shares and a blended EUR/USD exchange rate of 1.15 for fiscal 2026 planning purposes.

What Was Disclosed

Avantor disclosed its third-quarter fiscal 2026 financial results, including net sales, earnings, segment performance, balance sheet position, and cash flow, alongside an update to its full-year 2026 financial guidance across organic revenue growth, adjusted EPS, and free cash flow.